Safety assessment and pharmacodynamics of a novel ultra low molecular weight heparin (RO-14) in healthy volunteers--a first-time-in-human single ascending dose study.
暂无分享,去创建一个
R. Antonijoan | J. Fontcuberta | I. Gich | M. Barbanoj | M. Borrell | S. Rico | J. Martínez-González | M. Monreal
[1] R. Antonijoan,et al. Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers. , 2009, International journal of clinical pharmacology and therapeutics.
[2] A. Blann,et al. The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants , 2009, Vascular health and risk management.
[3] V. Laux,et al. Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra‐low‐molecular‐weight heparin, AVE5026 , 2009, Journal of thrombosis and haemostasis : JTH.
[4] A. Turpie,et al. AVE5026, a new hemisynthetic ultra‐low‐molecular‐weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery – TREK: a dose‐ranging study , 2009, Journal of thrombosis and haemostasis : JTH.
[5] B. Furie,et al. Mechanisms of thrombus formation. , 2008, The New England journal of medicine.
[6] J. Martínez-González,et al. Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism , 2008, Expert review of cardiovascular therapy.
[7] G. Raskob,et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[8] Elaine Gray,et al. Heparin and low-molecular-weight heparin , 2008, Thrombosis and Haemostasis.
[9] J. Fareed,et al. Why differentiate low molecular weight heparins for venous thromboembolism? , 2007, Environmental health perspectives.
[10] Scott R. Manalis,et al. Monitoring of heparin and its low-molecular-weight analogs by silicon field effect , 2006, Proceedings of the National Academy of Sciences.
[11] J. Hirsh,et al. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[12] P. Walsh,et al. The assembly of the factor X‐activating complex on activated human platelets , 2003, Journal of thrombosis and haemostasis : JTH.
[13] E. Racine. Differentiation of the Low‐Molecular‐Weight Heparins , 2001, Pharmacotherapy.
[14] R. Leadley. Coagulation factor Xa inhibition: biological background and rationale. , 2001, Current topics in medicinal chemistry.
[15] M. Prins,et al. For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same? , 2000, Thrombosis research.
[16] J. Weitz. Low-molecular-weight heparins. , 1997, The New England journal of medicine.
[17] M. L. Larsen,et al. Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238). , 1978, Thrombosis research.
[18] J. Fontcuberta,et al. Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, Bemiparin, at therapeutic subcutaneous doses. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[19] R. Hull,et al. Antithrombotic therapy for venous thromboembolic disease. , 1986, Chest.